Kole Roybal

I’m excited to share how a modular synthetic receptor called SNIPR opens new possibilities for immunotherapy by sensing both tumor-secreted factors and synthetic computationally designed soluble proteins: nature.com/articles/s4158….

🚨 New study for the lab! We developed SEED selection, a method to purify KnockIns at multiple loci in a single step. Better, It takes no space in the donor template, can be easily multiplexed and its all through negative selection! 👏👏 @ChrisRChang biorxiv.org/content/10.110…

This week on Science is Fun! syn bio prof @KoleRoybal @UCSF shares the exciting progress in immune cell therapies for cancer: podcasts.apple.com/us/podcast/sci…

By using #cancer's own powers, @UCSF & @NorthwesternMed scientists engineered T cells that are more much effective at killing cancer cells. The ‘Judo T-cell therapy’ “can survive & thrive in the harsh conditions that tumors create,” @KoleRoybal says. ucsfh.org/3UzwRyO

Such an important discovery published by the @KoleRoybal and @jaehyukchoimd labs relating to specific mutations that can drive non-physiologic T cell functional states. Implications for both our understanding of T cell biology and #cancer #immunotherapy approaches.

@Nature features breakthrough research from a team co-led by Gladstone’s @KoleRoybal, who conducted the study at @UCSF and in conjunction with @NorthwesternMed go.nature.com/42xxz1l

Awesome approach &discoveries by @KoleRoybal and @jaehyukchoimd that dramatically changes our understanding of what is possible for solid tumor cell therapy. Formed the basis for Moonlight Bio. nature.com/articles/s4158…

Read below about our exciting work that is now out @Nature led by @jcole_garcia of @UCSF @parkerici @GladstoneInst and @jay_daniels1 of @NUFeinbergMed. This is one of the most gratifying collaborations with @jaehyukchoimd -- tinyurl.com/nhdvhm6v

To accelerate this finding toward patient benefit, together w/ the researchers, we're building Moonlight Bio. This joint effort will enable the advancement of the enhanced cell therapy into first-in-human trials within years. Read the full study: nature.com/articles/s4158… (3/3)

Excited to share new PICI-enabled research from scientists at @UCSFCancer, @NUFeinbergMed & @GladstoneInst. The team, including @KoleRoybal, PhD, Center Director for the PICI Center at UCSF, identified a mutation that made engineered T cells 100x more potent w/o toxicity. (1/3)

Congrats! It will be great to have you on the west coast!

"It is my great pleasure to announce that Professor @MEBirnbaum has been promoted to Associate Professor With Tenure. He is making outstanding contributions to BE, MIT and our field with his scholarship, teaching, mentoring and service." BE Dept Head Angela Belcher

Thrilled to report in @natBME our new effort to improve the manufacturing and access of gene edited T cells. Awesome collab with the @RossWilsonLab and @MarsonLab. We developed a protein-based delivery for CRISPR systems in human primary cells. A 🧵 by Ross 👇🏼

Today we report that an engineered skin bacterium, swabbed gently on the head of a mouse, can unleash a potent immune response against a distant tumor. @yerinchen led the charge w/ help from @DjenetBousbaine, @VeinbachsA, @BelkaidLab. @ScienceMagazine 1/26 science.org/doi/10.1126/sc…

I am so incredibly humbled an honored by this award. Thank you to @AACR and @CancerResearch for all the support and to all the amazing trainees and colleagues I've been fortunate to work with.

This is why @DevotedHealth is doing so well… youtube.com/watch?v=SrK7Zh…